Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Статья

Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA)

L. V. StakhovskayaPirogov Russian National Research Medical University, Moscow, RussiaN. А. ShamalovPirogov Russian National Research Medical University, Moscow, RussiaД. Р. ХасановаResearch Institute of Cerebrovascular Pathology and Stroke of Pirogov Russian National Research Medical University, Moscow, RussiaЕ. В. МельниковаInterregional Clinical-Diagnostic Center, Kazan, RussiaA S AgafiinaCity Hospital #26, St. Petersburg, RussiaK. V. GolikovCity Hospital #40, St. Petersburg, RussiaЭ. И. БогдановCity General Hospital #2, St. Petersburg, RussiaA. A. YakupovaCity General Hospital #2, St. Petersburg, RussiaL. V. RoshkovskayaKazan State Medical University, Kazan, RussiaL. V. LukinykhNikolaev Hospital, St. Petersburg, RussiaTatiana Markovna LokshtanovaVsevolga Clinical Interregional Hospital, Leningrad Region, RussiaИ. Е. ПоверенноваPirogov City Clinical Hospital #1, Samara, RussiaL A ShepankevichSeredavin Samara Regional Clinical Hospital, Samara, Russia ,Research Institute Experimental and Clinical Medicine, Novosibirsk, Russia
2017en
ABI

Аннотация

AIM: To evaluate the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (IS). MATERIAL AND METHODS: A randomized double blind multicenter placebo-controlled, in parallel groups trial included 151 patients (62 men and 89 women) with hemispheric IS. Using a method of simple randomization, 150 patients (62 men and 88 women), aged 40-79 years, were randomized into two groups. Patients of Group I were treated with mexidol: 500 mg/day IV infusion for 10 days, followed by 125 mg tid (375 mg/day) PO for 8 weeks. Patients of Group II received the placebo according to the same scheme. The total duration of patients' participation in trial ranged from 67 to 71 days. RESULTS: By the end of treatment, the mean score on the modified Rankin scale (mRS) was lower in Group I compared to Group II (p=0.04). In Group I, the decrease in mRS mean score (Visit 1-5) was more prominent (p=0.023), percentage of patients with 0-2 scores by mRS scale (Visit 5) was higher (p=0.039), mean NIHSS score lower (p=0.035) in Visit 5 compared to group II. By the end of treatment, the decrease in mean NIHSS score in patients with diabetes mellitus was more prominent in Group I in comparison with Group II (p=0.038). In Group I, the dynamic of improvement of quality of life was more prominent and started from Visit 2 in general population and subpopulation of patients with diabetes mellitus. The share of patients with no problems with movement in space was higher in Group I (p=0.022). There were no statistically significant differences in frequency of side effects in patients of both groups. CONCLUSION: It is recommended to include mexidol in therapy of patients with IS in the acute and early rehabilitation stages.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0